ObsEva SA (OBSV) Announces Earnings Results

ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings data on Tuesday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.01), Briefing.com reports. ObsEva SA’s revenue for the quarter was up NaN% compared to the same quarter last year.

Shares of ObsEva SA (NASDAQ:OBSV) opened at $11.67 on Wednesday. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69.

WARNING: “ObsEva SA (OBSV) Announces Earnings Results” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/11/15/obseva-sa-obsv-announces-earnings-results.html.

A number of research firms have commented on OBSV. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ObsEva SA in a research note on Wednesday, November 8th. Royal Bank Of Canada reissued a “buy” rating and issued a $22.00 price objective on shares of ObsEva SA in a research note on Thursday, November 2nd. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday, October 18th. Credit Suisse Group began coverage on ObsEva SA in a research note on Monday, October 9th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Leerink Swann reissued an “outperform” rating and issued a $18.00 price objective on shares of ObsEva SA in a research note on Wednesday, August 16th. Six analysts have rated the stock with a buy rating, ObsEva SA has a consensus rating of “Buy” and a consensus price target of $18.83.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply